Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functionsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers analyzed stool samples from the Luxembourg Parkinson's Study, comparing 147 people with typical Parkinson's disease to 162 controls. They examined both microbial composition and the metabolic functions those microbes could perform.
How was it studied?
Samples underwent 16S rRNA gene sequencing to identify bacterial taxa. The team then used personalised metabolic modelling, combining microbiome data with genome-scale reconstructions of gut microbes, to predict secretion potential for 129 microbial metabolites.
What did they find?
Eight genera and seven species differed significantly in relative abundance between PD patients and controls, with patterns depending on sex, age, BMI, and constipation. Bilophila and Paraprevotella abundances tracked Hoehn and Yahr disease staging, and predicted secretion of nine metabolites changed in PD, including increased methionine and cysteinylglycine; predicted pantothenic acid production potential linked to specific non-motor symptoms.
Why it matters
The findings suggest gut microbiome alterations in Parkinson's disease are not just compositional but translate into functional metabolic changes that could affect host physiology and disease phenotype.